Supportive Therapies in Multiple Myeloma

Gleason, Charise; Nooka, Ajay K.; Lonial, Sagar

doi:10.6004/jnccn.2009.0064

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple myeloma, an incurable cancer of the bone marrow and the second most common haematological malignancy [ 4 ], exemplifies this changing face of cancer. Many myeloma patients experience a more chronic disease trajectory, coping with gradually progressing disease, interspersed with intervals of stable disease with minimal or maintenance treatment but lasting effects of high-dose chemotherapy [ 5 , 6 ]. This longer disease trajectory of cancer and the intensive treatments have led to a need to evaluate patient-reported outcomes in addition to traditional monitoring, such as response to treatment and toxicity profiles, in this condition.…”

Section: Introductionmentioning

confidence: 99%

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods

et al. 2017

View full text Add to dashboard Cite

PurposeThe Myeloma Patient Outcome Scale (MyPOS) was developed to measure quality of life in routine clinical care. The aim of this study was to determine its longitudinal validity, reliability, responsiveness to change and its acceptability.MethodsThis 14-centre study recruited patients with multiple myeloma. At baseline and then every two months for 5 assessments, patients completed the MyPOS. Psychometric properties evaluated were as follows: (a) confirmatory factor analysis and scaling assumptions (b) reliability: Generalizability theory and Rasch analysis, (c) responsiveness and minimally important difference (MID) relating changes in scores between baseline and subsequent assessments to an external criterion, (d) determining the acceptability of self-monitoring.Results238 patients with multiple myeloma were recruited. Confirmatory factor analysis found three subscales; criteria for scaling assumptions were satisfied except for gastrointestinal items and the Healthcare support scale. Rasch analysis identified limitations of suboptimal scale-to-sample targeting, resulting in floor effects. Test–retest reliability indices were good (R = > 0.97). Responsiveness analysis yielded an MID of +2.5 for improvement and -4.5 for deterioration.ConclusionsThe MyPOS demonstrated good longitudinal measurement properties, with potential areas for revision being the Healthcare Support subscale and the rating scale. The new psychometric approaches should be used for testing validity of monitoring in clinical settings.Electronic supplementary materialThe online version of this article (doi:10.1007/s11136-017-1660-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Management of MM begins with general measures, including intravascular volume repletion, hemodynamic support, controlling hypercalcemia (using intra venous saline, steroids and bisphos phonate therapy, dose adjusted according to renal function) and treating hyper uricemia (using allopurinol, rasburicase and/or hemodialysis) [45,46]. Certain medications should be avoided, including loop diuretics, NSAIDs and renin-angiotensin inhibitors.…”

Section: Managementmentioning

confidence: 99%

Management of myeloma-associated renal dysfunction in the era of novel therapies

Gaballa

Laubach

Schlossman

et al. 2012

Expert Review of Hematology

View full text Add to dashboard Cite

“…Improvements in supportive care will allow patients to gain the benefit of continuing with treatment, and understanding and managing toxicities will prevent premature discontinuation because of adverse reactions. 6 Supportive care for MM was reviewed in JNCCN 4 years ago 7 and by the British Committee for Standards in Hematology and UK Myeloma Forum. 8 This review focuses on advances in the management of bone-related complications, peripheral neuropathy, thrombosis, and risk of infection.…”

mentioning

confidence: 99%

Advances in Supportive Care for Multiple Myeloma

Raje

Yee

Roodman

2014

J Natl Compr Canc Netw

View full text Add to dashboard Cite

As patients with multiple myeloma live longer, helping them live better through improvements in supportive care is equally as vital. Intrinsic to the disease are bone-related complications at presentation and over the course of illness. Bisphosphonates have been an important therapy for ameliorating the risk of skeletal-related events, and work is ongoing to determine their optimal schedule. Patients with multiple myeloma also encounter several challenges related to their treatment, including peripheral neuropathy, thrombotic complications, and infections. These challenges are being addressed through a better understanding of the risk factors for developing these complications and by mitigating these risks through better dosing schemas and prophylaxis.

show abstract

Supportive Therapies in Multiple Myeloma

Cited by 4 publications

References 15 publications

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods

Management of myeloma-associated renal dysfunction in the era of novel therapies

Advances in Supportive Care for Multiple Myeloma

Contact Info

Product

Resources

About